Trial results

$SPRY — ARS-2

ARS Pharmaceuticals, Inc. (SPRY) ARS-2: trial results in Chronic spontaneous urticaria (CSU), 2027.

Research by Catalyst Intel

The catalyst

"The interim analysis population was fully enrolled as of May 2026, and we currently expect to report interim Phase 2b data in the first quarter of 2027, with full data later in 2027, which will inform the design of a potential Phase 3 registration program."

— ARS Pharmaceuticals, Inc., 10-Q filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

SPRY-ARS2-2026

Company

ARS Pharmaceuticals, Inc.

Kind

Trial results

Indication

Chronic spontaneous urticaria (CSU)

Window

2027-01-01 – 2027-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.